ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma

Cancer Biomarkers

Volumn 12, Issue 3, 2012, Pages 115-124

  Choi, Kyu Young ^a   Rho, Young Soo ^a   Kwon, Kee Hwan ^a   Chung, Eun Jae ^a   Kim, Jin Hwan ^a   Park, Il Seok ^a   Lee, Dong Jin ^a  

^a Ilsong Memorial Institute of Head and Neck Cancer   (South Korea)

Author keywords

ECRG1; FGFR4; Oral SCC; SNP

Indexed keywords

ARGININE; ECRG1 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLUTAMINE; GLYCINE; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; GINGIVA TUMOR; HUMAN; LYMPH NODE METASTASIS; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TONGUE CARCINOMA;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SERINE PROTEASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84876362727     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-130299     Document Type: Article

References (53)

1. Markopoulos A. Current aspects on oral squamous cell carcinoma. The Open Dentistry Journal 2012: 6: 126-130.
2. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 2008: 87: 14-32.
3. Lung T, Tascau OC, Almasan HA,Muresan O. Head and neck cancer, epidemiology and histological aspects-Part 1: A decade's results 1993-2002. J Craniomaxillofac Surg 2007: 35: 120-125.
4. Silverman S Jr. Demographics and occurrence of oral and pharyngeal cancers: the outcomes, the trends, the challenge. J Am Dent Assoc 2001: 132: 7-11.
5. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009: 45: 301-308.
6. Tanuma J, Izumo T, et al. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncology Reports 2010: 23: 739-744.
7. Marsh D, Suchak K, et al. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol 2011: 223: 470-81.
8. Klug C, Wutzl A, et al. Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: Grade of regression as crucial prognostic factor. Int J Oral Maxillofac Surg 2005: 34: 262-267. (Pubitemid 40309739)
9. Carinci F, Pelucchi S, Farina A, Bonsetti S, Mastranrea M, Calearo C. Site-dependent survival in cancer of the oral cavity. J Craniofac Surg 1997: 8: 399-404. (Pubitemid 27424818)
10. Shah JP. Cervical lymph nodes, Mosby 2003.
11. Schliephake H. Prognostic releVance of molecular markers of oral cancer-a review. Int J Oral Maxillofac Surg 2003: 32: 233-245. (Pubitemid 36700729)
12. Smith BD, Haffty BG, Sasaki CT. Molecular markers in head and neck squamous cell carcinoma: Their biological function and prognostic significance. Ann Otol Rhinol Laryngol 2001: 110: 221-228. (Pubitemid 32221648)
13. Garzino-Demo P, et al. Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma. J Craniomaxillofac Surg 2006: 34: 344-350.
14. Li Y, Zhang X, Huang G, Miao X, Guo L, Lin D, Lu SH. Identification of a novel polymorphism Arg290Gln of esophageal cancer related gene 1 (ECRG1) and its related risk to esophageal squamous cell carcinoma. Carcinogenesis 2006: 27: 798-802.
15. Blessmann M, Pohlenz P, et al. Single nucleotide polymorphism in esophageal cancer related gene 1: An analysis in resected oral squamous cell carcinoma patients. Int. J. Oral Maxillofac. Surg 2009: 38: 779-784.
16. WangY, Tang H, Lu S, Expression in E. coli of protein encoded by human esophageal cancer related gene-1. Zhonghua Zhong Liu Za Zhi 2000: 22: 198-200.
17. YueyinW, JianboW,HailinL,HuaijingT, LipingG, Shih-Hsin L. ECRG1, a novel esophageal gene, cloned and identified from human esophagus and its inhibition effect on tumors. Carcinogenesis 2008: 29: 157-160. (Pubitemid 351201754)
18. Zhao N, Huang G, Guo L, Lu SH. ECRG1, a novel candidate of tumor suppressor gene in the esophageal carcinoma, triggers a senescent program in NIH3T3 cells. Exp Biol Med (Maywood) 2006: 231: 84-90. (Pubitemid 43063980)
19. Su T, Liu H, Lu S. Cloning and identification of cDNA fragments related to human esophageal cancer. Zhonghua Zhong Liu Za Zhi 1998: 20: 254-257.
20. Lin SC, Chang MF, Chung MY, Chang CS, Kao SY, Liu CJ, ChangKW. Frequentmicrosatellite alterations of chromosome locus 4q13.1 in oral squamous cell carcinomas. J Oral Pathol Med 2005: 34: 209-213.
21. Bottcher RT, Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 2005: 26: 63-77. (Pubitemid 40209387)
22. Kim HJ, Kim JH, Bae SC, Choi JY, Kim HJ, Ryoo HM. The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem 2003: 278: 319-326.
23. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000: 7: 165-97.
24. Burke D, Wilkes D, Blundell TL, Malcolm S. Fibroblast growth factor receptors: Lessons from the genes. Trends Biochem Sci 1998: 23: 59-62. (Pubitemid 28085228)
25. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005: 16: 139-149. (Pubitemid 40616112)
26. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010: 5: 173-192.
27. da Costa Andrade VC, Parise O Jr, Hors CP, de Melo Martins PC, Silva AP, Garicochea B. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007: 82: 53-57. (Pubitemid 46038266)
28. Takahashi A, Sasaki H, Kim SJ, Kakizoe T, Miyao N, Sugimura T, Terada M, Tsukamoto T. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun 1999: 257: 855-859. (Pubitemid 29301531)
29. Bange J, Prechtl D, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg (388) allele. Cancer Res 2002: 62: 840-7. (Pubitemid 34126962)
30. Stadler CR, Knyazev P, Bange J, Ullrich A. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006: 18: 783-94. (Pubitemid 43208932)
31. Thussbas C, Nahrig J, et al. FGFR4 Arg388 allele is associated with resistance to adjuVant therapy in primary breast cancer. J Clin Oncol 2006: 24: 3747-55. (Pubitemid 46622313)
32. Ansell A, Farnebo L, Grenman R, Roberg K, Thunell LK. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol 2009: 45: 23-9.
33. Morimoto Y, Ozaki T, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 2003: 98: 2245-50. (Pubitemid 37392429)
34. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, Dragani TA. Functional FGFR4 Gly388Arg polymorphismpredicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005: 23: 7307-11. (Pubitemid 46202344)
35. Streit S, Mestel DS, Schmidt M, Ullrich A, Berking C. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. Br J Cancer 2006: 94: 1879-86. (Pubitemid 43882579)
36. Wang J, Stockton DW, IttmannM. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004: 10: 6169-78. (Pubitemid 39287523)
37. Yang YC, Lu ML, Rao JY, Wallerand H, Cai L, Cao W, Pantuck A, Dalbagni G, Reuter V, Figlin RA, Belldegrun A, Cordon-Cardo C, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer 2006: 95: 1455-8. (Pubitemid 44863347)
38. Becker N, Nieters A, Chang-Claude J. The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer. Cancer Epidemiol Biomarkers Prev 2003: 12: 582-3. (Pubitemid 36713656)
39. Jezequel P, Campion L, et al. G388R mutation of the FGFR4 gene is not releVant to breast cancer prognosis. Br J Cancer 2004: 90: 189-93. (Pubitemid 38174960)
40. Matakidou A, El Galta R, Rudd MF,Webb EL, Bridle H, Eisen T, Houlston RS. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer 2007: 96: 1904-7. (Pubitemid 46912027)
41. Mawrin C, Kirches E, et al. Analysis of a single nucleotide polymorphism in codon 388 of the FGFR4 gene in malignant gliomas. Cancer Lett 2006: 239: 239-45. (Pubitemid 43974867)
42. SpinolaM, Leoni VP, et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005: 14: 415-9.
43. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V and Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev 2000: 11: 295-302.
44. Cavallaro U and Christofori G.Multitasking in tumor progression: Signaling functions of cell adhesion molecules. Ann NY Acad Sci 2004: 1014: 58-66. (Pubitemid 38594791)
45. LeungHY,GullickWJ and LemoineNR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer 1994: 59: 667-675. (Pubitemid 24358591)
46. Jaakkola S, Salmikangas P, Nylund S, et al. Amplification of the FGFR4 gene in human breast and gynaecological cancers. Int J Cancer 1983: 54: 378-382.
47. Zhu Q, Liu T. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: A case control study.Mol Biol Rep 2012: 39: 8679-8685.
48. Webster MK and Donoghue DJ. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996: 15: 520-527. (Pubitemid 26044565)
49. Sibley K, Cuthbert-Heavens D and Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001: 20: 4416-4418.
50. Van Rhijn BW, Lurkin I, RadVanyi F, Kirkels WJ, Van der Kwast TH and Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3)mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001: 61: 1265-1268. (Pubitemid 34292538)
51. Streit S, Bange J, Fichtner A, Ihrler S, Issing W and Ullrich A. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 2004: 111: 213-217. (Pubitemid 38924697)
52. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008: 123: 2574-2579.
53. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008: 10: 847-856.